Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 3:48 AM ET

Sponsor Check › Person

Robert Weisskoff

Named as an officer, director or promoter on SEC Form D filings · MA, NJ, MN, OH, CA · Mar 24, 2015 → Oct 19, 2026

18deals (issuers)

$798.1Mreported sold

377investors

56Form D filings

2015–2026years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:17 AM ET · SEC enforcement last checked: not yet

The short version

Robert Weisskoff is listed as a director on 56 SEC Form D filings by 18 issuers between Jul 2009 and Oct 2026. Largest by amount reported sold: Caribou Biosciences, Inc. (Berkeley, CA — biotechnology — 2015–2021; $115M reported sold to 36 investors), Affinia Therapeutics Inc. (Waltham, MA — industry reported as "Other" — 2020–2025; $110M reported sold to 22 investors), ShouTi Inc. (South San Francisco, CA — biotechnology — 2021–2022; $100M reported sold to 30 investors), Xilio Therapeutics, Inc. (Waltham, MA — biotechnology — 2021; $95M reported sold to 17 investors), Checkmate Pharmaceuticals, Inc. (Cambridge, MA — biotechnology — 2020; $85.1M reported sold to 17 investors) and 13 more (all listed below).

What this means That is a lot of deals — 18 separate companies raised money with this person listed as director, over about 17 years. Across those companies the filings report $798.1M sold in total.

Listed alongside David P. Bonita (17 shared filings), Caley Castelein (10 shared filings), James F. Dempsey (10 shared filings), Joshua Bilenker (10 shared filings), Mark Gold (10 shared filings) and 153 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.

1 of the issuers belongs to the sponsor group Viewray (2 issuers, $41.1M reported sold, 2010–2017).

What this means A sponsor group is one team that sets up a new company for each deal. Viewray has 2 companies on file and $41.1M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), state securities regulators (AZ, CA, DE, TX, WA) — none found. Not yet searched: SEC enforcement releases (search queued; results are added automatically).

What this means Nothing turned up where we looked (2 sources). That does not prove there is nothing — it means none was found in those sources on that date.

What the community is saying

Nothing found on Reddit, BiggerPockets or community forums for high-net-worth investors (searched Oct 24, 2026) — search queued; this line updates when it has run.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

Not yet searched — search queued

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

SEC search queued. Results are added automatically.

3. Bankruptcies

None found in sources searched

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:17 AM ET.

4. Differences between public sources

Not made for individual people — comparisons cover issuers and sponsor groups

5. Money to insiders

2 of 49 offerings report sales commissions totalling $8,726,979; 0 report finder's fees; 4 report proceeds to related persons totalling $1,508,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Oct 19, 2026 D Adela, Inc. File 021-601738	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 23, 2026 D Adela, Inc. File 021-581637	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 14, 2025 D Affinia Therapeutics Inc. File 021-560739	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 8, 2025 D Adela, Inc. File 021-550950	$0	$0	$0	None listed on this filing	EDGAR ↗
Nov 19, 2024 D Zenflow, Inc. File 021-529812	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 29, 2024 D/A Adela, Inc. File 021-489534	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 14, 2024 D Adela, Inc. File 021-505327	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 14, 2024 D Adela, Inc. File 021-505329	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 10, 2022 D ShouTi Inc. File 021-428629	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 21, 2021 D ShouTi Inc. File 021-417842	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 21, 2021 D ShouTi Inc. File 021-417848	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 21, 2021 D ShouTi Inc. File 021-417860	$3,087,000	$0	$0	SVB Leerink LLC BrokerCheck CRD 39011 ↗	EDGAR ↗
Oct 21, 2021 D Basecamp Bio Inc. File 021-417877	$0	$0	$0	None listed on this filing	EDGAR ↗
May 20, 2021 D/A Zenflow, Inc. File 021-396049	$0	$0	$0	None listed on this filing	EDGAR ↗
May 6, 2021 D Affinia Therapeutics Inc. File 021-398517	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 5, 2021 D Caribou Biosciences, Inc. File 021-391380	$5,639,979	$0	$0	SVB Leerink LLC BrokerCheck CRD 39011 ↗	EDGAR ↗
Jan 21, 2021 D Xilio Therapeutics, Inc. File 021-387002	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 18, 2020 D Checkmate Pharmaceuticals, Inc. File 021-369265	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 24, 2020 D Checkmate Pharmaceuticals, Inc. File 021-365710	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 27, 2020 D Affinia Therapeutics Inc. File 021-363863	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 12, 2020 D/A Tempest Therapeutics, Inc. File 021-306741	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 28, 2020 D/A Checkmate Pharmaceuticals, Inc. File 021-347004	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 13, 2018 D Farapulse, Inc. File 021-319020	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 27, 2017 D/A Zenflow, Inc. File 021-296213	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 11, 2017 D Farapulse, Inc. File 021-290358	$0	$0	$0	None listed on this filing	EDGAR ↗
May 25, 2016 D Caribou Biosciences, Inc. File 021-263801	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 3, 2016 D Farapulse, Inc. File 021-258524	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 15, 2015 D/A Amphora Medical, Inc. File 021-197489	$0	$0	$768,000 A portion of the proceeds will be used to pay the salaries of the executive officers in the ordinary course of business.	None listed on this filing	EDGAR ↗
Mar 24, 2015 D/A Caribou Biosciences, Inc. File 021-225136	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 4, 2015 D VIEWRAY INC File 021-235161	$0	$0	$0	None listed on this filing	EDGAR ↗
Jan 8, 2015 D VIEWRAY INC File 021-231795	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 3, 2013 D VIEWRAY INC File 021-207317	$0	$0	$0	None listed on this filing	EDGAR ↗
Sep 25, 2013 D BIOCONNECT SYSTEMS INC File 021-203529	$0	$0	$400,000 (est.)	None listed on this filing	EDGAR ↗
May 17, 2013 D VIEWRAY INC File 021-196697	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 21, 2013 D/A VIEWRAY INC File 021-188257	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 5, 2012 D BIOCONNECT SYSTEMS INC File 021-187890	$0	$0	$215,000 (est.)	None listed on this filing	EDGAR ↗
Mar 15, 2012 D VIEWRAY INC File 021-174983	$0 (est.)	$0 (est.)	$0 (est.)	None listed on this filing	EDGAR ↗
Jan 13, 2012 D BIOCONNECT SYSTEMS INC File 021-171774	$0	$0	$125,000 (est.)	None listed on this filing	EDGAR ↗
Aug 26, 2011 D/A VIEWRAY INC File 021-161755	$0	$0	$0 (est.)	None listed on this filing	EDGAR ↗
Sep 28, 2010 D TRANSAVE INC File 021-148242	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 26, 2010 D VIEWRAY INC File 021-145470	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 9, 2010 D ACCURI CYTOMETERS INC File 021-144654	$0	$0	$0 (est.)	None listed on this filing	EDGAR ↗
Jun 25, 2010 D TRANSAVE INC File 021-144039	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 9, 2010 D ACORN CARDIOVASCULAR INC File 021-143220	$0	$0	$0	None listed on this filing	EDGAR ↗
May 28, 2010 D TETRAPHASE PHARMACEUTICALS INC File 021-142724	$0	$0	$0	None listed on this filing	EDGAR ↗
Dec 9, 2009 D Ikano Therapeutics Inc. File 021-101585	$0	$0	$0	None listed on this filing	EDGAR ↗
Nov 3, 2009 D TRANSAVE INC File 021-50801	$0	$0	$0	None listed on this filing	EDGAR ↗
Sep 23, 2009 D TETRAPHASE PHARMACEUTICALS INC File 021-94056	$0	$0	$0	None listed on this filing	EDGAR ↗
Jul 14, 2009 D ACCURI CYTOMETERS INC File 021-102715	$0	$0	$0 (est.)	None listed on this filing	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 18

Every issuer that named Robert Weisskoff on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Biotechnology

Adela, Inc.

Foster City, CA · Aug 11, 2023 → Oct 19, 2026 · 7 filings

Oct 19, 2026 · D · $12,000,000 sold of $12,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
Apr 23, 2026 · D · $5,000,000 sold of $5,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 8, 2025 · D · $25,425,442 sold of $27,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 29, 2024 · D/A · $48,540,780 sold of $49,317,173 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
Feb 14, 2024 · D · $3,296,554 sold of $3,296,554 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
Feb 14, 2024 · D · $1,187,700 sold of $1,187,700 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
Aug 11, 2023 · D · $28,031,993 sold of $29,199,991 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $48.5M from 11 investors (100% of the $12M target) as of the latest filing. Robert is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other

Affinia Therapeutics Inc.

Waltham, MA · Mar 27, 2020 → Oct 14, 2025 · 3 filings

Oct 14, 2025 · D · $13,268,335 sold of $45,000,000 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
May 6, 2021 · D · $109,999,955 sold of $109,999,955 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 27, 2020 · D · $38,522,942 sold of $68,522,920 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $110M from 22 investors (100% of the $45M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Health Care

Zenflow, Inc.

South San Francisco, CA · Dec 27, 2017 → Nov 19, 2024 · 4 filings

Nov 19, 2024 · D · $19,422,855 sold of $25,203,352 · 36 investors · min. $1 · role: Director EDGAR ↗
May 20, 2021 · D/A · $24,368,845 sold of $24,368,845 · 43 investors · min. $1 · role: Director EDGAR ↗
Apr 15, 2021 · D · $23,699,998 sold of $23,699,998 · 40 investors · min. $1 · role: Director EDGAR ↗
Dec 27, 2017 · D/A · $31,494,746 sold of $32,224,519 · 86 investors · min. $1 · role: Director EDGAR ↗

Raised $31.5M from 86 investors (100% of the $25.2M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

ShouTi Inc.

South San Francisco, CA · Oct 21, 2021 → Jan 10, 2022 · 4 filings

Jan 10, 2022 · D · $6,999,917 sold of $6,999,917 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 21, 2021 · D · $100,000,022 sold of $100,000,022 · 30 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 21, 2021 · D · $32,000,640 sold of $32,000,640 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
Oct 21, 2021 · D · $25,999,992 sold of $25,999,992 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100M from 30 investors (100% of the $7M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗

Sources

Biotechnology

Basecamp Bio Inc.

South San Francisco, CA · Oct 21, 2021

Oct 21, 2021 · D · $9,000,000 sold of $14,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $9M from 9 investors (64% of the $14M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗

Sources

Biotechnology

Caribou Biosciences, Inc.

Berkeley, CA · Mar 24, 2015 → Mar 5, 2021 · 3 filings

Mar 5, 2021 · D · $114,999,613 sold of $114,999,613 · 36 investors · min. No minimum reported · role: Director EDGAR ↗
May 25, 2016 · D · $14,459,306 sold of $30,070,244 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 24, 2015 · D/A · $11,549,904 sold of $11,549,904 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $115M from 36 investors (100% of the $115M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Biotechnology

Xilio Therapeutics, Inc.

Waltham, MA · Jan 21, 2021

Jan 21, 2021 · D · $50,249,990 sold of $50,249,990 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $95M from 17 investors (100% of the $50.2M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗

Sources

Biotechnology

Checkmate Pharmaceuticals, Inc.

Cambridge, MA · Jan 28, 2020 → Jun 18, 2020 · 3 filings

Jun 18, 2020 · D · $85,083,280 sold of $100,083,274 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
Apr 24, 2020 · D · $10,000,000 sold of $10,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 28, 2020 · D/A · $15,999,999 sold of $15,999,999 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $85.1M from 17 investors (85% of the $100.1M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Other Health Care

Tempest Therapeutics, Inc.

South San Francisco, CA · Mar 1, 2018 → Feb 12, 2020 · 3 filings

Feb 12, 2020 · D/A · $83,186,733 sold of $100,186,733 · 10 investors · min. $1 · role: Director EDGAR ↗
Feb 27, 2019 · D/A · $48,186,738 sold of $70,186,738 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 1, 2018 · D · $25,186,738 sold of $70,186,738 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $83.2M from 10 investors (83% of the $100.2M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Farapulse, Inc.

Menlo Park, CA · Mar 3, 2016 → Aug 13, 2018 · 3 filings

Aug 13, 2018 · D · $11,999,993 sold of $12,000,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 11, 2017 · D · $5,000,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 3, 2016 · D · $14,999,173 sold of $23,999,173 · 35 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $15M from 35 investors (100% of the $12M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Other Health Care

Amphora Medical, Inc.

Maple Grove, MN · Jun 5, 2013 → Jul 15, 2015 · 2 filings

Jul 15, 2015 · D/A · $12,782,106 sold of $12,782,106 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 5, 2013 · D · $600,000 sold of $1,250,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12.8M from 12 investors (100% of the $12.8M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Technology · group: Viewray

VIEWRAY INC

Oakwood Village, OH · Jul 26, 2010 → Mar 4, 2015 · 10 filings

Mar 4, 2015 · D · $15,000,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
Jan 8, 2015 · D · $16,273,385 sold of $16,800,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 3, 2013 · D · $14,999,993 sold of $14,999,993 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
May 17, 2013 · D · $14,999,998 sold of $17,432,178 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Feb 21, 2013 · D/A · $10,872,354 sold of $12,153,073 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Dec 12, 2012 · D · $5,872,355 sold of $6,660,099 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
Mar 15, 2012 · D · $26,305,075 sold of $26,305,075 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
Aug 26, 2011 · D/A · $10,336,599 sold of $10,350,000 · 15 investors · min. $1,280 · role: Director EDGAR ↗
Jun 23, 2011 · D · $10,000,000 sold of $10,223,950 · 8 investors · min. $1,280 · role: Director EDGAR ↗
Jul 26, 2010 · D · $19,998,591 sold of $19,998,591 · 8 investors · min. $23,000 · role: Director EDGAR ↗

Raised $26.3M from 18 investors (100% of the $15M target) as of the latest filing. Robert is listed as director on 10 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

BIOCONNECT SYSTEMS INC

Ambler, PA · Jan 13, 2012 → Sep 25, 2013 · 3 filings

Sep 25, 2013 · D · $9,069,922 sold of $12,500,000 · 7 investors · min. $25,000 · role: Director EDGAR ↗
Dec 5, 2012 · D · $1,485,794 sold of $1,600,000 · 6 investors · min. $4,504 · role: Director EDGAR ↗
Jan 13, 2012 · D · $469,196 sold of $938,392 · 6 investors · min. $1,407 · role: Director EDGAR ↗

Raised $9.07M from 7 investors (73% of the $12.5M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Biotechnology

TRANSAVE INC

Monmouth Jct., NJ · Nov 3, 2009 → Sep 28, 2010 · 3 filings

Sep 28, 2010 · D · $2,000,000 sold of $6,000,000 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
Jun 25, 2010 · D · $5,499,999 sold of $5,855,619 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
Nov 3, 2009 · D · $5,542,573 sold of $12,000,000 · 0 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.54M (92% of the $6M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other Health Care

ACCURI CYTOMETERS INC

Ann Arbor, MI · Jul 14, 2009 → Jul 9, 2010 · 2 filings

Jul 9, 2010 · D · $6,000,000 sold of $6,000,000 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
Jul 14, 2009 · D · $3,749,971 sold of $4,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6M from 27 investors (100% of the $6M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other Technology

ACORN CARDIOVASCULAR INC

St. Paul, MN · Jun 9, 2010

Jun 9, 2010 · D · $478,476 sold of $500,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $478K from 12 investors (96% of the $500K target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals

TETRAPHASE PHARMACEUTICALS INC

Watertown, MA · Sep 23, 2009 → May 28, 2010 · 2 filings

May 28, 2010 · D · $44,750,000 sold of $45,000,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
Sep 23, 2009 · D · $10,000,000 sold of $29,627,203 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $44.8M from 14 investors (99% of the $45M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Pharmaceuticals

Ikano Therapeutics Inc.

Saddle Brook, NJ · Dec 9, 2009

Dec 9, 2009 · D · $892,719 sold of Indefinite · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $893K from 14 investors as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

Robert Weisskoff — WA, 1 issuer, Sep 10, 2021 → Jul 25, 2023 · no shared issuer

People around Robert 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

Person

David P. Bonita

Director · 17 shared filings (2 issuers) · also on 26 other issuers

David P. Bonita is on 28 issuers in total — a repeat sponsor. Their page lists every one.

Person

Caley Castelein

Director · 10 shared filings (1 issuer) · also on 6 other issuers

Caley Castelein is on 7 issuers in total — a repeat sponsor. Their page lists every one.

Person

James F. Dempsey

Director, Executive Officer, Promoter · 10 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Joshua Bilenker

Director · 10 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Mark Gold

Director · 10 shared filings (1 issuer) · also on 7 other issuers

Mark Gold is on 8 issuers in total — a repeat sponsor. Their page lists every one.

Person

David Chandler

Executive Officer · 9 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Peter Roemer

Director · 8 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

David Scheer

Executive Officer, Director, Promoter · 7 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Paul Brown

Director · 7 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Maneesh Jain

Director, Promoter · 7 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Daniel Diniz De Carvalho

Executive Officer, Promoter · 7 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Anne-Renee Hartman

Executive Officer · 7 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Alan Williams

Executive Officer · 7 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Gregory M. Ayers

Executive Officer, Director, Promoter · 6 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Lisa Alderson

Executive Officer, Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Andrew ElBardissi

Director · 6 shared filings (2 issuers) · also on 10 other issuers

Andrew ElBardissi is on 12 issuers in total — a repeat sponsor. Their page lists every one.

Person

Raymond Stevens

Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Chris A. Raanes

Executive Officer, Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Priscilla Huang

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

David Grayzel

Director · 4 shared filings (2 issuers) · also on 13 other issuers

David Grayzel is on 15 issuers in total — a repeat sponsor. Their page lists every one.

Person

Jay Andrew

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Petpiboon Prasit

Director · 4 shared filings (2 issuers) · also on 5 other issuers

Petpiboon Prasit is on 7 issuers in total — a repeat sponsor. Their page lists every one.

Person

Daniel Auerbach

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Radu Cautis

Director · 4 shared filings (1 issuer) · also on 4 other issuers

Radu Cautis is on 5 issuers in total — a repeat sponsor. Their page lists every one.

Person

Shreya Mehta

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Cuiping Gu

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Jun Yoon

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

BRYAN KIM

Director · 4 shared filings (1 issuer) · also on 8 other issuers

BRYAN KIM is on 9 issuers in total — a repeat sponsor. Their page lists every one.

Person

Ramy Farid

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Jessica Lifton

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Ting Xie

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Karla Jarvis

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Chen Ming Yu

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Charles Hadley

Director · 4 shared filings (2 issuers) · also on 5 other issuers

Charles Hadley is on 7 issuers in total — a repeat sponsor. Their page lists every one.

Person

Rick Modi

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Luc Vandenberghe

Director · 3 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Sean Nolan

Director · 3 shared filings (1 issuer)

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Alex Barkas

Director · 3 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Weisskoff. Their page shows their other deals.

Person

Corey Goodman

Director · 3 shared filings (1 issuer) · also on 20 other issuers

Corey Goodman is on 21 issuers in total — a repeat sponsor. Their page lists every one.

Person

Richard S. Kollender

Director · 3 shared filings (1 issuer) · also on 6 other issuers

Richard S. Kollender is on 7 issuers in total — a repeat sponsor. Their page lists every one.

The team behind the deals

Sponsor group

Viewray

2 issuers · 15 filings · $41.1M reported sold · 2010–2017

V ViewRay, Inc. Other Technology · $26.7M sold · 2015
V VIEWRAY INC Other Technology · $26.3M sold · 2010 · listed

One team, 2 deal companies. Robert Weisskoff is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Weisskoff.

Same business address

48 other issuers file from the same address

Epicrispr Biotechnologies, Inc. South San Francisco, CA · 2026
Root Capital Inc. Cambridge, MA · 2013
Lansing Street Real Estate Fund LLC - Series AZ Ambler, PA · 2026
Quince Therapeutics, Inc. South San Francisco, CA · 2016
Lansing Street Real Estate Fund LLC - Series AY Ambler, PA · 2026
NGM Bio Holdings, Inc. South San Francisco, CA · 2024
Orso Beta Arbitrage, LP South San Francisco, CA · 2026
Lansing Street Real Estate Fund LLC - Series AX Ambler, PA · 2026
Lansing Street Real Estate Fund LLC - Series AW Ambler, PA · 2026
Box Holdings LP South San Francisco, CA · 2017
Premise Ventures Fund I, L.P. South San Francisco, CA · 2025
SPRUCE BIOSCIENCES, INC. South San Francisco, CA · 2020
Lansing Street Real Estate Fund LLC - Series AV Ambler, PA · 2025
C10 Labs Fortuna 1 SPV LLC Cambridge, MA · 2025
iSono Health, Inc. South San Francisco, CA · 2025
MENTA GLOBAL, LP South San Francisco, CA · 2009
Converge Fund III, LP Cambridge, MA · 2023
YUMA AI Inc. Cambridge, MA · 2024
Lansing Street Real Estate Fund LLC - Series AG Ambler, PA · 2022
Lansing Street Real Estate Fund LLC - Series AU Ambler, PA · 2024
Lansing Street Real Estate Fund LLC - Series AT Ambler, PA · 2024
Lansing Street Real Estate Fund LLC - Series AR Ambler, PA · 2024
Lansing Street Real Estate Fund LLC - Series AQ Ambler, PA · 2024
Lansing Street Real Estate Fund LLC - Series AS Ambler, PA · 2024
Converge Fund I-Annex, LP Cambridge, MA · 2024
Harpoon Therapeutics, Inc. South San Francisco, CA · 2017
Lyra Therapeutics, Inc. Watertown, MA · 2009
Kogniz Inc. South San Francisco, CA · 2022
Acrivon Therapeutics, Inc. Watertown, MA · 2021
Day One Biopharmaceuticals Holding Co LLC South San Francisco, CA · 2021
Demetrix, Inc. Berkeley, CA · 2017
Zikani Therapeutics, Inc. Watertown, MA · 2015
SutroVax, Inc. Foster City, CA · 2015
Arsenal Medical, Inc. Watertown, MA · 2011
VALENTX INC Maple Grove, MN · 2009
Amphivena Therapeutics, Inc. South San Francisco, CA · 2013
Ideaya Biosciences, Inc. South San Francisco, CA · 2016
OPPORTUNITY PARTNERS LP Saddle Brook, NJ · 2014
Tricida, Inc. South San Francisco, CA · 2014
ViewRay, Inc. Oakwood Village, OH · 2015
Pursuit Vascular, Inc. Maple Grove, MN · 2012
Saddlebrook Partners, LP Saddle Brook, NJ · 2015
VERACYTE, INC. South San Francisco, CA · 2010
FLUIDIGM CORP South San Francisco, CA · 2009
COMPARENETWORKS INC South San Francisco, CA · 2010
SUNESIS PHARMACEUTICALS INC South San Francisco, CA · 2009
Ionix Medical Inc. Maple Grove, MN · 2009
Crick Information Technologies, Inc. Maple Grove, MN · 2009

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Waltham, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Robert Weisskoff appears on a new Form D, or when a court case or SEC action is matched to them. See plans →

Robert Weisskoff

The short version

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

5. Money to insiders

Deals 18

People around Robert 40

The team behind the deals

48 other issuers file from the same address

Registrations and other filings

Adviser registration (Form ADV)

Other offering types (Regulation A and Regulation Crowdfunding)

Look further

Social and web

Courts

Securities regulators

Business registries

Change history

Request a correction

Add a response

Monitor this person